The Company identifies and sources innovative therapeutic drug candidates globally, and develops these drug candidates in accordance to the United States Food and Drug Administration regulatory standards to feed the product development pipelines of the pharmaceuticals industry.
The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive efficacy results from its Phase IIb dose-ranging clinical trial of PAC-113. Pacgen also has an early stage research program. The most advanced candidate is a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.
January 27, 2009
Pacgen Signs Research Collaboration Agreements
November 30, 2009
Pacgen Reports Second Quarter Financial Results
September 1, 2009
Pacgen Reports First Quarter Financial Results
August 13, 2009
Pacgen Completes Acquisition of Xphase Pharmaceuticals